logo
welcome
Reuters

Reuters

In weight loss battle, Novo and Lilly face growing offensive from licensed copies

Reuters
Summary
Nutrition label

80% Informative

Novo Nordisk and Eli Lilly expanding sales of popular diabetes and weight-loss drugs.

Cheap copies of their patented remedies are winning approval from some regulators overseas.

The growing number of licenced copies could depress prices for anti-obesity medicines and risk a spillover effect into important markets such as India .

A month 's supply of Semavic , used for diabetes and containing semaglutide, costs 4,420.20 Russian rubles ($ 42.76 ) in Russia .

Ozempic, Wegovy , and Rybelsus have not launched in Bangladesh , a Novo spokesperson told Reuters .

VR Score

91

Informative language

98

Neutral language

46

Article tone

formal

Language

English

Language complexity

73

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links